Abstract
The aim of the present study was to investigate the role of CSF cytochrome c levels and auditory event-related potentials (AERPs) on the progress of mild cognitive impairment (MCI) to Alzheimers disease (AD). Fifty one patients diagnosed with MCI and fourtneen healthy individuals underwent lumbar puncture at baseline and their CSF cytochrome c levels were determined. A follow-up examination of cytochrome c levels took place in 20 patients after 11 months and in this period five of the patients progressed to AD. ERP examinations were also performed in all patients both at baseline and follow-up. MCI patients had significantly higher cytochrome c levels compared to healthy controls (Mann-Whitney test, Z=-2.110, p=0.018). Compared to MCI patients who remained stable, the AD-converters, had a higher increase over time in cytochrome c levels (Mann-Whitney test, p=0.002; effect size r=0.63) and significantly prolonged N200 latency (Mann-Whitney test, p < 0.001; effect size r=0.50). Amongst investigated ERP variables, only N200 amplitude was significantly correlated with CSF cytochrome c levels (rs=0.310, p=0.03). Both parameters were proved capable of discriminating AD converters from those MCI patients who remained stable, with sensitivity and specificity > 75%. Our results suggest that conversion from MCI to AD is associated with a marked elevated N200 latency at baseline and a high increase in cytochrome c levels during a relatively short period of time, and that both parameters could be possibly considered as candidate markers for the discrimination between MCI patients who convert to AD and those who remain stable.
Keywords: Mild cognitive impairment, Alzheimer's disease, cytochrome c, auditory event-related potentials, N200 latency
Current Alzheimer Research
Title: Prediction of Conversion from Mild Cognitive Impairment to Alzheimer ’ s Disease by CSF Cytochrome c Levels and N200 Latency
Volume: 6 Issue: 3
Author(s): V. T. Papaliagkas, G. Anogianakis, M. N. Tsolaki, G. Koliakos and V. K. Kimiskidis
Affiliation:
Keywords: Mild cognitive impairment, Alzheimer's disease, cytochrome c, auditory event-related potentials, N200 latency
Abstract: The aim of the present study was to investigate the role of CSF cytochrome c levels and auditory event-related potentials (AERPs) on the progress of mild cognitive impairment (MCI) to Alzheimers disease (AD). Fifty one patients diagnosed with MCI and fourtneen healthy individuals underwent lumbar puncture at baseline and their CSF cytochrome c levels were determined. A follow-up examination of cytochrome c levels took place in 20 patients after 11 months and in this period five of the patients progressed to AD. ERP examinations were also performed in all patients both at baseline and follow-up. MCI patients had significantly higher cytochrome c levels compared to healthy controls (Mann-Whitney test, Z=-2.110, p=0.018). Compared to MCI patients who remained stable, the AD-converters, had a higher increase over time in cytochrome c levels (Mann-Whitney test, p=0.002; effect size r=0.63) and significantly prolonged N200 latency (Mann-Whitney test, p < 0.001; effect size r=0.50). Amongst investigated ERP variables, only N200 amplitude was significantly correlated with CSF cytochrome c levels (rs=0.310, p=0.03). Both parameters were proved capable of discriminating AD converters from those MCI patients who remained stable, with sensitivity and specificity > 75%. Our results suggest that conversion from MCI to AD is associated with a marked elevated N200 latency at baseline and a high increase in cytochrome c levels during a relatively short period of time, and that both parameters could be possibly considered as candidate markers for the discrimination between MCI patients who convert to AD and those who remain stable.
Export Options
About this article
Cite this article as:
Papaliagkas T. V., Anogianakis G., Tsolaki N. M., Koliakos G. and Kimiskidis K. V., Prediction of Conversion from Mild Cognitive Impairment to Alzheimer ’ s Disease by CSF Cytochrome c Levels and N200 Latency, Current Alzheimer Research 2009; 6 (3) . https://dx.doi.org/10.2174/156720509788486626
DOI https://dx.doi.org/10.2174/156720509788486626 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The miRNAs and Epithelial-Mesenchymal Transition in Cancers
Current Pharmaceutical Design Lichen Depsidones as Potential Novel Pharmacologically Active Compounds
Mini-Reviews in Organic Chemistry Leukaemia Infection Diagnosis and Intestinal Flora Disorder
Current Molecular Medicine Leveraging Cell Cycle Analysis in Anticancer Drug Discovery to Identify Novel Plasmodial Drug Targets
Infectious Disorders - Drug Targets Enhancement of Contractile Force Generation of Artificial Skeletal Muscle Tissues by Mild and Transient Heat Treatment
Current Pharmaceutical Biotechnology Ultrasound-Based Multimodal Molecular Imaging and Functional Ultrasound Contrast Agents
Current Pharmaceutical Design Synthesis and Anticancer Activity Evaluation of Some Benzothiazole-Piperazine Derivatives
Anti-Cancer Agents in Medicinal Chemistry The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics p53 Gene Family: Structural, Functional and Evolutionary Features
Current Genomics Circulating Tumor Cells (CTCs) as a Liquid Biopsy Material and Drug Target
Current Drug Targets Hexokinase II: The Integration of Energy Metabolism and Control of Apoptosis
Current Medicinal Chemistry Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry 1,3,4-Thiadiazolo (3,2-Α) Pyrimidine-6-Carbonitrile Scaffold as PARP1 Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives
Current Pharmaceutical Design Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols
Current Pharmaceutical Design Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy
Current Medicinal Chemistry Paving Roads for New Drugs in Oncology
Recent Patents on Anti-Cancer Drug Discovery Cellular and Humoral Responses following Minimally Invasive Surgery: Role of Reactive Oxygen Species
Current Metabolomics MicroRNAs in Organogenesis and Disease
Current Molecular Medicine